Events

Jane Grogan is Executive VP and Head of Research at Biogen, the 12th largest biotech in the world by market cap and the oldest independent biotech company on the East Coast. Biogen has FDA-approved medicines for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Friederich’s ataxia, multiple sclerosis, postpartum depression, and spinal muscular atrophy. Biogen applies deep understanding of human biology and leverages different modalities to advance first-in-class treatments and is currently focused on further expanding its pipeline in rare disease and immunology. Join us for an inside look at Biogen’s R&D, the challenges it faces and its approaches to solving them, and lessons Jane has learned in her career, including 15 years at Genentech.

Register for the Livestream

About the Speaker

Jane Grogan, Ph.D. is Executive Vice President (E.V.P.) and Head of Research at Biogen. Dr. Grogan joined Biogen in 2023, bringing nearly two decades of experience leading biotech research, including fifteen years with Genentech. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio and ArsenalBio, both cell and gene therapy companies. During her time at Genentech, she served in several increasingly senior roles across Immunology and Immuno-oncology, covering research strategies and drug development across RA, Lupus, MS, IBD and Cancer. Preceding her career in the Biotechnology Industry, Dr. Grogan completed her Ph.D. in immunology at Leiden University and her B.Sc in Biochemistry and Pharmacology from the University of Melbourne.